The present invention provides for a method for producing hydrogen peroxide comprising: (a) contacting a methanol with a methanol oxidase bound with a flavin adenine dinucleotide (FAD) cofactor, such that the methanol is oxidized into a formaldehyde and the FAD cofactor is reduced into FADH2; (b) contacting the formaldehyde with the methanol oxidase or a formate oxidase bound with a FAD cofactor, such that the formaldehyde is oxidized into a formate and the FAD is reduced into FADH2; and (c) contacting oxygen with one or more of the FADH2 to produce hydrogen peroxide and oxidize FADH2 into FAD. The present invention also provides for a fusion protein comprising any two or all of methanol oxidase, formate oxidase, and formaldehyde dismutase.
Methodology was developed for transformation of methionine residues into homocysteine derivatives. Methionine residues can undergo alkylation reactions at low pH to yield sulfonium ions, which can then be selectively demethylated to give alkyl homocysteine residues. This process tolerates many functional groups.
The present invention provides for a synthetic transcription factor (TF) comprising (a) a DNA-binding domain of a transcription factor linked to (b) an effector domain, and (c) optionanlly a nuclear localization sequence (NLS). The present invention provides for a nucleic acid encoding an effector domain of the present invention. The DNA-binding domain can be a deactivated RNA-guided nuclease variant of Cas9 (dCas9).
A therapeutic agent delivery catheter system includes an elongate tube defining a lumen therein formed from biocompatible material and sized to insert in a patient. The elongate tube has a length that extends to reach a treatment region of the patient. A pattern of slits forming microvalves penetrates an outer wall of the tube. The slits are small enough to remain closed to contain a solution of therapeutic agent, and are configured to open in response to a pressure pulse in the lumen and emit a microjet of therapeutic agent from each slit in the pattern of slits distributed along the rostro caudal extent of the implanted catheter.
The present disclosure relates to targeted degradation platform technology. For example, the present disclosure relates to bispecific binding agents for degrading endogenous proteins, whether membrane-associated or soluble, using the lysosome pathway. The disclosure also provides methods useful for producing such agents, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various disorders.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
6.
IMAGING FLOW CYTOMETER USING SPATIAL-TEMPORAL TRANSFORMATION
Methods, systems, and devices are disclosed for imaging particles and/or cells using flow cytometry. In one aspect, a method includes transmitting a light beam at a fluidic channel carrying a fluid sample containing particles; optically encoding scattered or fluorescently-emitted light at a spatial optical filter, the spatial optical filter including a surface having a plurality of apertures arranged in a pattern along a transverse direction opposite to particle flow and a longitudinal direction parallel to particle flow, such that different portions of a particle flowing over the pattern of the apertures pass different apertures at different times and scatter the light beam or emit fluorescent light at locations associated with the apertures; and producing image data associated with the particle flowing through the fluidic channel based on the encoded optical signal, in which the produced image data includes information of a physical characteristic of the particle.
Methods and systems for pulmonary function testing of a subject are provided. Aspects of the present invention include methods and systems configured to generate flow volume curves and compute lung function parameters of a subject and determine potential clinical interpretations of pulmonary function. In addition, the present invention offers advantages including (i) measuring lung function without initial calibration of spirometer information, (ii) the ability to use spirometer information to develop a machine learning based algorithm which will eventually measure lung function without needing spirometer information at all, (iii) computing metrics such as chest and waist width and sitting height of subject.
G06T 7/246 - Analysis of motion using feature-based methods, e.g. the tracking of corners or segments
G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
Disclosed herein are novel edible fungal products with various colors, flavors, shapes, sizes, densities, and biological activities, and methods of producing these products. An exemplary process uses fungal biomass deactivation and pellet-coating steps which allow control over the texture, flavor, color, and nutrient characteristics of the resulting product. The coating and deactivation process can be utilized in concert with the other methods of this invention to create a wide array of products with novel flavor, texture, and nutrient characteristics, depending on the intended application.
Ocular serpinA3 activity is modulated to treat glaucoma by neuroprotection, comprising administering to an eye in need thereof a serpinA3 polypeptide or a nucleic acid encoding the serpinA3 polypeptide.
The instant disclosure sets forth a process for re-activating a mineral residue. The process includes providing a mineral residue, which includes a core and a shell around the core. In certain examples, the core comprises calcium (Ca), magnesium (Mg), or a combination thereof. The Ca and Mg is not present as elemental Ca or Mg but rather as a compound of Ca or of Mg, such as but not limited to Ca(OH)2 or Mg(OH)2. In certain examples, the shell comprises an oxide, a hydroxide, a carbonate, a silicate, a sulfite, a sulfate, a chloride, a nitrate, or nitrite, of calcium (Ca) or of magnesium (Mg), or a combination thereof. The process includes (a) fractionating the mineral residue; (b) contacting the mineral residue with an acid and fractionating the mineral residue; or (c) contacting the mineral residue with a base and fractionating the mineral residue. As a result, the mineral residue's core is exposed. In some examples, the shell is passivating and inhibits the Ca or Mg, or both, in the core from reacting with carbon dioxide (CO2). By exposing the core as described herein, a mineral residue's reactivity with carbon dioxide is increased.
B01J 20/04 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
B01J 20/30 - Processes for preparing, regenerating or reactivating
C04B 28/18 - Compositions of mortars, concrete or artificial stone, containing inorganic binders or the reaction product of an inorganic and an organic binder, e.g. polycarboxylate cements containing mixtures of the silica-lime type
C04B 40/02 - Selection of the hardening environment
11.
Compositions and Methods of Treating Ocular Diseases
The present disclosure provides recombinant adeno-associated virus (AAV) virions with altered capsid protein, where the recombinant AAV (rAAV) virions exhibit greater ability to cross barriers between intravitreal fluid and retinal cells, and thus greater infectivity of a retinal cell compared to wild-type AAV, and where the rAAV virions comprise a heterologous nucleic acid. The present disclosure provides methods of delivering a gene product to a retinal cell in an individual.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David (USA)
Georgia Tech Research Corporation (USA)
The Regents of the University of California (USA)
Inventor
Butts, Jessica
Mcdevitt, Todd C.
Abstract
Methods of generating spinal cord glutamatergic interneurons (V2a interneurons) from human pluripotent stem cells (hPSCs) are provided. A method of the present disclosure may include culturing a first population of hPSCs in vitro in a neural induction medium that includes: a retinoic acid signaling, pathway activator; a sonic hedgehog, (Shh) signaling pathway activator; and a Notch signaling pathway inhibitor, wherein the culturing results in generation of a second population of cultured cells containing CHX10+ V2a interneurons. Also provided are non-human animal models that include the hPSC-derived spinal cord glutametergic interneurons, and methods of producing the non-human animal models.
The present disclosure provides a list of genes, and the proteins encoded by these genes, that modulate and/or participate in the synthesis of the biopolymer suberin. The genes described here are useful in methods for producing genetically modified plants or breeding plants with increased or decreased suberin. Such plants can contain modified, mutated, or engineered candidate peptides; or have disrupted or enhanced expression using methods such as clustered regularly-interspaced short palindromic repeats (CRISPR)/CRISPR associated (Cas) nuclease, an antisense nucleic acid, a zinc finger nuclease (ZFN), or a transcription activator-like effector (TALE) nuclease. Increased suberin has a positive influence on response to plant water stress and pathogen protection, and a long-lasting role as a carbon sink in soil; and decreased suberin encourages symbioses and nutrient uptake.
The disclosure further provides diagnostic, prognostic and therapeutic methods, which are based, at least in part, on determination of the identity of a genotype of interest identified herein.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
15.
SYSTEMS AND METHODS FOR DIFFERENTIAL AND NON-DIFFERENTIAL NAVIGATION WITH CELLULAR SIGNALS
Processes and device configurations are provided for navigation using communications signal observables and using differential and non-differential frameworks. Communication signals, such as cellular communication signals may be used to obtain position estimates of a device such as a rover or unmanned aerial vehicle. Frameworks are provided for determination of position estimates with and without the use of a base station device. Processes can include use of position estimates to aid navigation.
G01S 5/00 - Position-fixing by co-ordinating two or more direction or position-line determinations; Position-fixing by co-ordinating two or more distance determinations
G01S 5/02 - Position-fixing by co-ordinating two or more direction or position-line determinations; Position-fixing by co-ordinating two or more distance determinations using radio waves
H04B 7/26 - Radio transmission systems, i.e. using radiation field for communication between two or more posts at least one of which is mobile
H04W 4/40 - Services specially adapted for particular environments, situations or purposes for vehicles, e.g. vehicle-to-pedestrians [V2P]
The invention provides, for the first time, cells that comprise enhanced CD16, CD32, or CD64 expression to evade antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). The cells may be pluripotent cells, including hypoimmune pluripotent cells (HIP) or ABO blood type O Rhesus Factor negative HIP cells (HIPO−), that further comprise the enhanced CD16, CD32, or CD64 expression. The invention encompasses cells derived from the pluripotent cells.
The invention provides gene targets whose restoration leads to genome stabilization in host cells, such as Chinese Hamster Ovary (CHO) cells. Many DNA repair genes are mutated in CHO cells which compromises their ability to repair naturally occurring DNA damage, in particular double-strand breaks (DSBs). Unrepaired DSBs can give rise to chromosomal instability which, in turn, can lead to loss of transgenes from the genome. As a consequence, protein titer can drop significantly, rendering protein production unprofitable. The invention provides a set of mutated DNA repair genes whose restoration yields significant improvement in DSB repair, genome stability, and protein titer.
Described herein are methods, materials, kits, devices, and assays for use in screening, detection, and treatment of diabetes, including diabetes mellitus and gestational diabetes mellitus (GDM). The amount of a plurality of metabolic markers present in a test sample obtained from the subject is measured, followed by comparing the amount of the metabolic markers present in the test sample to reference levels of the markers; and identifying a subject as susceptible to, or as having, diabetes when the amount of each of the measured markers present in the test sample is increased or decreased relative to the reference levels. Also provided is a method of treating diabetes in a subject when the amount of each of the measured markers present in the test sample is increased or decreased relative to the reference levels.
Disclosed herein are CMV-specific CARs. In some embodiments. the present invention is directed to a method of treating, reducing, or inhibiting an infection by a cytomegalovirus in a subject, which comprises administering to the subject (a) an expression vector that encodes a CMV-specific CAR as described herein, or (b) one or more cells that are transduced with the expression vector.
The present disclosure relates generally to methods of treating a brain injury, preferably a traumatic brain injury, hypoxic brain injury, brain infection, or stroke, comprising administering to a subject an inhibitor of the complement pathway.
The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.
Present implementations are directed to nonvolatile memory devices with charge trap transistor structures. Example implementations can include a method of memory storage, by programming a first data node operatively coupled to a first charge trap transistor to a first level above a threshold, decreasing, below the threshold, a first voltage at the first charge trap transistor, increasing, above the threshold, the first voltage at the first charge trap transistor, and reprogramming, the first data node to the first level, in response to an interruption of the first voltage at the first charge trap transistor caused by the decreasing and the increasing.
Methods for converting mixtures of anthocyanins occurring in fruit or vegetable juice or extract into particular anthocyanin molecules having desirable colorant properties are provided herein. The method of the present disclosure can be employed to increase the amount of particular anthocyanin molecules, while lowering the total number of anthocyanin molecules present in the natural juice and/or extract. The disclosure is also directed to anthocyanin molecules prepared by the methods of present disclosure and to enzymes capable of catalyzing reactions that provide such effects.
C12P 17/16 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing two or more hetero rings
A23L 5/43 - Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives
C12P 19/60 - Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
Resuscitation and ventilation monitoring devices are provided. A device includes an inlet in fluid communication with airflows exchanged with lungs of a patient and an airflow meter for measuring characteristics of the airflows. A user may provide a controller with patient information, e.g., height, weight, gender, or age, via a measurement selector, enabling the controller to determine acceptable ranges of measured airflow characteristics. The device may determine a current mode of ventilation and associated ventilator settings based on the measured airflow characteristics. The device may also identify and filter out artifacts present in the ventilation signal, and determine whether a respiratory failure phenotype is present in the ventilation. If the current mode of ventilation and associated ventilator settings fall outside an acceptable range, the ventilation is classified as off-target and the controller may cause a sensory alarm to alert the user. The device may suggest a corrective action based on the type of off-target ventilation detected. The device may also continuously analyze ventilation to determine changes in lung compliance over time and to identify pathological changes over time. The device may work within a network of devices and user interfaces via wired or wireless communication, and is not restricted to or dependent on the type of ventilatory device with which a patient is being supported.
Certain embodiments of the invention provide cell penetrating peptides. Certain embodiments of the invention provide methods and compositions for intracellular delivery. Certain embodiments of the invention provide methods and compositions for targeted delivery.
C07K 7/64 - Cyclic peptides containing only normal peptide links
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
In various embodiments method are provided for generating expression cassettes and gene therapy vectors comprising those cassettes that recapitulate the spatiotemporal pattern of expression of the endogenous gene. In certain embodiments the methods comprise (i) selecting a target gene; (ii) identifying putative regulatory elements associated with the target gene; (iii) determining if the regulatory element is a key regulatory element and (iv) providing a list of the key regulatory elements identified in step (iii).
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
The present disclosure relates to targeted degradation platform technology. For example, the present disclosure relates to bispecific binding agents for degrading endogenous proteins, whether membrane-associated or soluble, using the lysosome pathway. The disclosure also provides methods useful for producing such agents, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various disorders.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The disclosure provides compositions comprising amino acids, individually and in combination, and methods of making the compositions and methods of using the compositions as pharmaceutically active agents to, inter alia, treat disease in animals, including humans.
Systems and methods for fabricating an optoelectronic transceiver with a tunable traveling wave modulator and an analog coherent receiver to transmit and receive wavelength-multiplexed optical signals in accordance with embodiments of the invention are disclosed. In one embodiment, a network switch includes a plurality of ports configured to transmit and receive optical signals and electrical current signals, a plurality of optoelectronic transmitters using a traveling wave modulator and driver biasing, and a plurality of analog coherent receivers.
G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour
G02F 1/21 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour by interference
Systems and methods are provided for excitation spectral microscopy using frame-synchronized acousto-optic scanning of fluorescent excitation wavelengths. Linear unmixing of the images of targets of components that are individually labeled with different fluorophores can be simultaneously imaged with high temporal resolution and low crosstalk and the local abundance of each fluorophore at each pixel can be quantified. Fluorophore decomposed micrographs of the sample can be obtained by rendering the abundance in each pixel as an image.
Ultrasound imaging is a non-invasive, non-radioactive, and low cost technology for diagnosis and identification of implantable medical devices in real time. Developing new ultrasound activated coatings is important to broaden the utility of in vivo marking by ultrasound imaging. Ultrasound responsive macro-phase segregated micro-composite thin films were developed to be coated on medical devices composed of multiple materials and with multiple shapes and varying surface area. The macro-phase segregated films having silica micro-shells in polycyanoacrylate produces strong color Doppler signals with the use of a standard clinical ultrasound transducer. Electron microscopy showed a macro-phase separation during slow curing of the cyanoacrylate adhesive, as air-filled silica micro-shells were driven to the surface of the film. The air sealed in the hollow space of the silica shells acted as an ultrasound contrast agent and echo decorrelation of air exposed to ultrasound waves produces color Doppler signals.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings
A61B 8/12 - Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
The present disclosure relates to compounds that are capable of inhibiting PRMT8 and/or upregulating SirT1. The disclosure further relates to methods of treating neurodegenerative diseases and disorders (e.g., Alzheimer's disease).
C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
C07C 237/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
C07C 237/04 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
C07D 209/48 - Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
C07C 237/20 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Pistacia vera L.) designated as ‘UC Westside’, to be used advantageously as a pollenizer for commercial female pistachio varieties. ‘UC Westside’ blooms later in the spring than most existing male pistachio cultivars and is particularly characterized by a reduced juvenility period, dense blooms in years with low chill, good pollen viability, and improved bloom synchrony with standard female pistachio varieties, especially ‘Kerman’. It may be used as a replacement for the male cultivar ‘Peters’.
The present disclosure relates to an engineered antibody that co-engages a cell type-selective (or specific) antigen (guide) and a signaling receptor (effector) on a target cell. In some instances, the engineered antibody is capable of modulating a signaling pathway on a target cell. In other embodiments, an engineered antibody of the present disclosure is administered to a subject for the treatment of a disease or condition.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A method is provided for treating a skin wound. In accordance with the method, an ultrasound image is obtained of a skin wound on a patient. The ultrasound image is processed to extract information that is correlated to a degree of wound healing. The degree of wound healing is assessed based at least in part on the extracted information. The skin wound is treated based at least in part based on the assessed degree of wound healing.
Disclosed herein are methods of increasing or decreasing endogenous interferon amounts in subjects which comprise inhibiting, reducing, increasing, enhancing, or stabilizing MORC3 in the subjects.
Set forth herein is a composition that includes a fungal pellet and animal cells, wherein the animal cells are in connection with the fungal pellet. The animal cells can be located on the exterior surface of the fungal pellet, the interior of the fungal pellet, or both. The fungal pellet can include intact fungal cells. The fungal pellet can be substantially inviable. In an example, the pellet can be heat-treated, chemically treated, or lyophilized. The animal cells can be mammalian cells, wherein the mammalian cells may be non-human mammalian cells.
Methods for the efficient isolation and use of pluripotent adipose-derived stem cells (PASCs) are provided. In certain embodiments the methods involve providing an adipose tissue sample from which the stromal vascular fraction is co-cultured with the adipocyte fraction. PASCs can be isolated with a high degree of purification without requiring an additional cell enrichment process (e.g. cell sorting). PASCs and their conditioned media can be used for tissue regeneration within hours of harvesting the adipose tissue, and without requiring cell expansion. PASCs can grow as floating individual cells, as clusters of cells, or attached to surface(s) of the culture vessel. PASCs do not produce teratomas in vivo, nor do they induce immunorejection upon transplantation, and they achieve a high efficiency in grafting. The cells and compositions can be used for cell therapy and to screen new drugs.
Bioartificial ultrafiltration devices comprising a scaffold comprising a population of cells enclosed in a matrix and disposed adjacent a plurality of channels are provided. The population of cells provides molecules such as therapeutic molecules to a subject in need thereof and is supported by the nutrients filtered in an ultrafiltrate from the blood of the subject. The plurality of channels in the scaffold facilitate the transportation of the ultrafiltrate and exchange of molecules between the ultrafiltrate and the population of cells.
B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
The present disclosure generally relates to, inter alia, a new class of receptors engineered to modulate transcriptional regulation in a ligand-dependent manner. Particularly, the new receptors, even though derived from Notch, do not require the Notch negative regulatory regions previously believed to be essential for the functioning of the receptors. In addition, the new receptors described herein incorporate an extracellular oligomerization domain to promote oligomer formation of the chimeric receptors. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various health conditions such as cancers.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
42.
SURGICAL PERCEPTION FRAMEWORK FOR ROBOTIC TISSUE MANIPULATION
A method for tracking a surgical robotic tool being viewed by an endoscopic camera, images of the surgical tool are received from the endoscopic camera and surgical tool joint angle measurements are received from the surgical tool. Predetermined features of the surgical tool on the images of the surgical tool are detected to define an observation model to be employed by a Bayesian Filter. A lumped error transform and observable joint angle measurement errors are estimated using the Bayesian Filter. The lumped error transform compensates for errors in a base-to-camera transform and non-observable joint angle measurement errors. Pose information over time of the surgical tool is determined with respect to the endoscopic camera using kinematic information of the robotic tool, the surgical tool joint angle measurements, the lumped error transform and the observable joint angle measurement errors. The pose information is provided to a surgical application.
A61B 34/20 - Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
Methods, systems, and devices are disclosed for encapsulating biological entities with preservation of their biological activity. In one aspect, a method of encapsulating a biological entity includes templating a biocompatible material onto a biological structure to form a coating structure enclosing the biological structure, the coating structure having a size in the nanometer range, in which the coated biological structure preserves its biological activity within the coating structure. In some implementations of the method, the biological structure includes a virus and the biocompatible material includes silica.
A microporous wick and a method for non-thermal solar desalination is disclosed, which includes placing a capillary wick in a brine containing sodium chloride (NaCl), the capillary wick comprising a plurality of bonded aluminum nitride (Al—N) microparticles and illuminating the capillary wick with a light source.
C02F 1/52 - Treatment of water, waste water, or sewage by flocculation or precipitation of suspended impurities
F28D 15/04 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes with tubes having a capillary structure
An implantable device includes an outer tubular member defining a longitudinal axis and a lumen. The outer tubular member includes: an outer wall portion having a plurality of first strands defining a plurality of first openings therebetween, the outer wall portion having a first porosity; and an inner baffle portion disposed within the lumen, the inner baffle portion including a plurality of second strands defining a plurality of second openings therebetween, the inner baffle portion having a second porosity that is lower than the first porosity of the outer wall portion.
A61F 2/90 - Stents in a form characterised by wire-like elements; Stents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
A61F 2/01 - Filters implantable into blood vessels
A61F 2/86 - Stents in a form characterised by wire-like elements; Stents in a form characterised by a net-like or mesh-like structure
46.
METHOD OF FABRICATING A RESONANT CAVITY AND DISTRIBUTED BRAGG REFLECTOR MIRRORS FOR A VERTICAL CAVITY SURFACE EMITTING LASER ON A WING OF AN EPITAXIAL LATERAL OVERGROWTH REGION
A method for fabricating a quality and manufacturable aperture for light emitting elements, such as vertical cavity surface emitting lasers (VCSELs), using epitaxial later overgrowth (ELO). A bar comprised of island-like III-nitride semiconductor layers is grown on a substrate using a growth restrict mask, and the island-like III-nitride semiconductor layers are fabricated into light-emitting resonating cavities across a smallest length of the bar. Apertures for the resonating cavities are also fabricated along the smallest length of the bar on wing regions of the epitaxial lateral overgrowth. Distributed Bragg reflectors (DBRs) are fabricated as mirrors for the resonant cavities on the bottom and top of the wing regions of the epitaxial lateral overgrowth.
H01S 5/183 - Surface-emitting [SE] lasers, e.g. having both horizontal and vertical cavities having only vertical cavities, e.g. vertical cavity surface-emitting lasers [VCSEL]
H01S 5/02 - Structural details or components not essential to laser action
47.
System and Method for Determining a Device Safe Zone
A method for determining a region for safe placement of a device in a medical image includes receiving a medical image, detecting at least one anatomic landmark in the medical image using at least one deep convolutional neural network, determining the region for safe placement of the device based on the detected at least one anatomic region using a semantic network, and displaying the region for safe placement of a device on the medical image using a display.
Parallel plate devices for hemofiltration or hemodialysis are provided. A parallel plate device includes a parallel plate assembly having an aligned stack of stackable plate subunits, each stackable plate subunit having a through channel for blood, where the blood channels are opened up at opposite ends of the parallel plate assembly. The parallel plate assembly is configured to form filtrate/dialysate channels interleaved with the blood channels, adjacent channels being separated by a silicon nanoporous filtration membrane. A blood conduit adaptor is attached to the parallel plate assembly at each of the ends, and is configured to distribute blood to or collect blood from the blood channels. Also provided are systems and methods for using the parallel plate devices.
A vehicle path routing method is disclosed for determining a lowest-cost path from a source to a destination. A graph representing a road network includes vertices and edges between vertices. Vertices in the graph represent locations and edges represent paths between locations. Edge weights represent costs, such as travel times and energy consumptions for travel along edges of the graph. Significantly, edge weights are represented as probability distributions. The routing method partitions the edges into multiple tiers, for which convolutions of probability distributions can and cannot be feasibly replaced with functional approximations. A Dijkstra search of the graph from a vehicle origin to a vehicle destination computes, for vertices along a path, convolutions of distributions and sums of functional approximations.
Antiviral compounds can be utilized to mitigate viral activity of enveloped viruses in an infected host. In some instances, a virally infected biological cell is contacted with an antiviral to mitigate viral activity in the biological cell. In some instances, a virally infected animal is administered an antiviral to mitigate viral activity in the animal. In some instances, an animal is prophylactically administered an antiviral to mitigate viral activity in the animal. Therapeutics and treatments involving antiviral compounds are also described.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Systems and methods for use by a person lying in a generally prone or generally lateral position on a resting surface are disclosed. A system may include a head-mountable image display device that when used by the person at least partially occludes the person's view of a surrounding environment. The system may further include a support assembly configured to support at least a portion of the person's head in a raised position above or level with at least one of the resting surface and the head-mountable image display device. An opening may be formed in the support assembly that is sized to permit the person, while lying in the generally prone or generally lateral position, to view at least a portion of the head-mountable image display device through a portion of the support assembly. Methods of using such a system in a medical or other procedure are also disclosed.
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
C07C 235/20 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
C07C 317/08 - Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
C07D 207/14 - Nitrogen atoms not forming part of a nitro radical
C07D 211/58 - Nitrogen atoms attached in position 4
C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Provided are compositions, methods and uses relating to an adjuvant which comprises, or consists essentially of, or consists of a cowpea mosaic virus (CPMV) particle and its combination with one or more antigens or cells, such as an irradiated cancer cell comprising the one or more antigens.
Provided herein are methods for treating cancer comprising administering to a subject in need thereof an adamantane derivative, or a pharmaceutically acceptable salt thereof, such as rimantadine or amantadine. In some embodiments, the adamantane derivative is PEGylated.
The present invention relates generally to materials and methods for detection of bacteria, and for testing and determination of antibiotic susceptibility of bacteria in specimens of bodily fluid and other samples. The invention also relates to materials and methods for monitoring the physiological response of bacteria to antimicrobial agents, and for reducing background and increasing sensitivity of assays that involve the detection and/or measurement of RNA, such as rRNA. The invention provides kits comprising an RNase packaged for use in the methods described herein.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
57.
COMPOSITIONS AND METHODS FOR TARGETING AND KILLING ALPHA-V BETA-3-POSITIVE CANCER STEM CELLS (CSCS) AND TREATING DRUG RESISTANT CANCERS
Provided are compositions and methods for treating or ameliorating a cancer by targeting cell surface-expressed αvβ3 (avb3) polypeptides in Cancer Stem Cells (CSCs) to kill the CSCs, thus treating ameliorating or slowing the development of cancers caused or initiated by or sustained by cancer or tumor cells, or Cancer Stem Cells (CSCs), expressing αvβ3 polypeptides on their cell surfaces. Provided are compositions and methods for targeting and killing αvβ3-positive Cancer Stem Cells (CSCs) and treating drug resistant cancers. In alternative embodiments, compositions and methods as provided herein use an antibody that can specifically bind to human αvβ3 that also comprises an Fc portion that can mediate antibody-dependent un-mediated cytotoxicity (ADCC) killing of cancer or tumor cells by macrophages; for example, use a humanized antibody to αvβ3 that has been modified to include an engineered Fc portion that specifically binds to human macrophages.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present disclosure describes a high-throughput methodology for rapid and highly personalized screenings to identify efficacious anti-tumor immunotherapy regiments. In one embodiment, therapeutic agents or a combination thereof are screened by co-culturing tumor shaped organoid extrudates with a population of immune cells taken from the same patient. Reduced tumor cell functions or increased immune cell functions in the presence of the therapeutic agents or combination thereof would identify the therapeutic agents or combination thereof for treating the tumor in the patient.
This disclosure provides systems, methods, and apparatus related to an ultrasonic microphone and an ultrasonic acoustic radio. In one aspect a system includes a transmitter and a receiver. The receiver comprises a membrane. The membrane comprises a single layer or multiple layers of a two-dimensional material. The receiver is operable to receive sound waves in a frequency range, with the frequency range being the ultrasonic frequency range.
G01H 11/06 - Measuring mechanical vibrations or ultrasonic, sonic or infrasonic waves by detecting changes in electric or magnetic properties by electric means
The present disclosure relates to compounds that are capable of modulating the WNT/Beta-Catenin pathway. The disclosure further relates to methods of treating colorectal cancer and other WNT/Beta-Catenin mediated cancers.
C07C 235/62 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho- position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
C07C 237/04 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
C07C 311/07 - Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
C07D 213/89 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
C07D 295/088 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C07D 295/15 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07C 237/38 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a ring other than a six-membered aromatic ring
C07D 213/06 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
C07D 213/38 - Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present disclosure provides methods of preparing concrete products comprising carbonation of brucite-containing concrete. The present disclosure further provides brucite containing concrete mixtures that are useful in the present methods.
C04B 28/10 - Lime cements or magnesium oxide cements
C04B 40/02 - Selection of the hardening environment
C04B 40/00 - Processes, in general, for influencing or modifying the properties of mortars, concrete or artificial stone compositions, e.g. their setting or hardening ability
63.
EFFICIENT INTEGRATION OF MANUFACTURING OF UPCYCLED CONCRETE PRODUCT INTO POWER PLANTS
Arizona Board of Regents on Behalf of Arizona State University (USA)
Inventor
Sant, Gaurav
Pilon, Laurent G.
Wang, Bu
Neithalath, Narayanan
Wei, Zhenhua
Young, Benjamin
Falzone, Gabriel D.
Simonetti, Dante
Abstract
A manufacturing process of a concrete product includes: (1) extracting calcium from solids as portlandite; (2) forming a cementitious slurry including the portlandite; (3) shaping the cementitious slurry into a structural component; and (4) exposing the structural component to carbon dioxide sourced from a flue gas stream, thereby forming the concrete product.
Disclosed herein are methods of treating cancer. Some such methods include administration of a first anti-cancer agent that increases CD46 expression on the surface of a cancer cell. Some embodiments include administration of a second anti-cancer agent that binds CD46. The second anti-cancer agent may include an immunoconjugate comprising a CD46 binding domain and effector agent.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
This disclosure provides a synthesized version of S. felis C4 antimicrobial peptide as a topical antibiotic. S. felis C4 can be used as a probiotic strain of skin bacteria that can be transplanted onto the diseased skin of dogs, cats and dairy cows to outcompete and kill pathogenic bacteria that are causing infections such as bacterial pyoderma and mastitis.
Internal cervical exams during labor pose multiple challenges, including infection risk, subjectivity, invasiveness, and discomfort. A monitoring system described herein enables non-invasive and accurate measurement of cervical dilation and assessment of the baby's station. By inserting a narrow linear ultrasound probe through the working channel, high-resolution ultrasound images of the cervix can be obtained, eliminating the need for painful and subjective exams, reducing infection risk, and enhancing patient comfort. Moreover, the ultrasound capability allows for potential monitoring of maternal and fetal blood oxygenation levels, providing a comprehensive picture of fetal well-being.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters
Disclosed herein is a system and methods for leaf detection and extraction. The extracted leaf may be used for leaf water potential analysis. In some embodiments, the method comprises identifying the leaf from a point cloud based on an image, determining a pose of the leaf based on the point cloud, and cutting and storing the leaf based on the pose of the leaf.
An acoustically driven ferromagnetic resonance (ADFMR) device has a piezoelectric element comprised of piezoelectric material, first and second electrodes arranged in a vertical stack with the piezoelectric element to activate the piezoelectric element to generate an acoustic wave, a radio frequency voltage source electrically connected to the first electrode, a magnet comprised of a magnetostrictive material in the vertical stack with the first and second electrodes and the piezoelectric element to receive the acoustic wave, wherein the acoustic wave resonates at a ferromagnetic resonance of the magnetostrictive material, and a readout circuit to detect a change in the acoustic wave by detecting one of an output voltage amplitude, a change in impedance or a reflection of the acoustic wave in the magnet to measure an unknown magnetic field in which the ADFMR device resides and as experienced at the magnetostrictive element.
G01N 24/10 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using electron paramagnetic resonance
69.
DETERMINISTIC MECHANOPORATION FOR CELL ENGINEERING
Intracellular delivery of a genetic construct to immune cells including: obtaining a deterministic mechanoporation (DMP) platform that includes a substrate having a surface and a plurality of capture sites, each said capture site having a boundary shape at the surface adapted and configured to support thereon a cell, and each said capture site having a bottom and including a sub-micron-scale projection extending from the bottom toward the surface of the substrate, wherein said projection is adapted and configured to penetrate a cell membrane and/or wall of the cell, and wherein the substrate has a plurality of aspiration vias situated at the bottom of the capture sites; introducing the cells to the surface in a liquid media; capturing the cells within the capture sites by applying a first hydrodynamic force; applying a second hydrodynamic force on the captured cell and locally rupturing the membrane and/or wall of the cell with the projection, introducing the genetic construct into the cells, and releasing the porated cells from the capture sites. Also disclosed are methods of chimeric antigen receptor (CAR) T cell adoptive immunotherapy and T cell receptor (TCR) therapy.
The current disclosure provides systems and methods for enhancing the audio/visual experience of a participant in a hybrid or in-situ meeting. In one example, a communications system comprises a plurality of electronic devices, each corresponding to a participant in a gathering of multiple participants, wherein one or more of the plurality of electronic devices is located in a physical meeting space, and machine executable instructions, that when executed cause the communications system to connect each of the plurality of electronic devices to a meeting platform corresponding to the physical meeting space, determine relative positions of the plurality of electronic devices, select an audio stream to transmit to the plurality of electronic devices based on sound feeds received by microphones in the plurality of electronic devices, and adjust the audio stream to each of the plurality of electronic devices based on the relative positions of the plurality of electronic devices.
A method for identifying a current context and determining a sensor combination based on the current environment. The method may comprise accepting a plurality of sensor outputs and implementing a CNN to convert the sensor outputs into a plurality of features that can be used to identify the context through use of a gating algorithm that additionally determines which sensors have the most importance and which have little or no importance. The method may further comprise executing sensor fusion in a manner corresponding to the context. For example, the context determines whether early fusion or late fusion should be implemented and which sensor outputs should be included in the said fusion.
G06V 10/70 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning
G06V 10/80 - Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level
G06V 10/771 - Feature selection, e.g. selecting representative features from a multi-dimensional feature space
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 491/056 - Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
G01N 33/66 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
74.
METHOD FOR RELAXING SEMICONDUCTOR FILMS INCLUDING THE FABRICATION OF PSEUDO-SUBSTRATES AND FORMATION OF COMPOSITES ALLOWING THE ADDITION OF PREVIOUSLY UN-ACCESSIBLE FUNCTIONALITY OF GROUP lll-NITRIDES
The present disclosure describes porous GaN layers and/or compliant substrates used to enable relaxation of previously strained top layers and the deposition of relaxed or partially relaxed on top. Relaxed In GaN layers are fabricated without generation of crystal defects, which can serve as base layers for high performance long wavelength light emitting devices (LEDs, lasers) solar cells, or strain engineered transistors. Similarly, relaxed AlGaN layers can serve as base layers for high performance short wavelength UV light emitting devices (LEDs, lasers) solar cells, or wide bandgap transistors.
H01L 33/32 - Materials of the light emitting region containing only elements of group III and group V of the periodic system containing nitrogen
H01L 33/16 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a particular crystal structure or orientation, e.g. polycrystalline, amorphous or porous
H01L 33/12 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a stress relaxation structure, e.g. buffer layer
H01L 25/075 - Assemblies consisting of a plurality of individual semiconductor or other solid state devices all the devices being of a type provided for in the same subgroup of groups , or in a single subclass of , , e.g. assemblies of rectifier diodes the devices not having separate containers the devices being of a type provided for in group
H01L 33/20 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a particular shape, e.g. curved or truncated substrate
75.
ANTITHROMBIN HEPARAN SULFATE FOR DETECTION AND TREATMENT OF CANCER
Methods of detecting and treating an epithelial carcinoma, such as pancreatic ductal adenocarcinoma cancer or bladder cancer, expressing antithrombin-binding heparan sulfate (HSAT) in a subject, comprising combining a biological sample of the subject containing HSAT with antithrombin and detecting binding of HSAT and the antithrombin, optionally determining that the antithrombin inhibits factor Xa.
Methods, systems, and devices are disclosed for collecting and transferring naturally-produced sweat containing an analyte to a biosensor and/or biofuel cell to estimate a concentration of the analyte corresponding to the analyte's concentration in blood and/or for producing electricity. In some aspects, a device includes a substrate, a plurality of electrodes disposed on the substrate and operable to detect an analyte in naturally-produced sweat of an individual, and a sweat permeation layer including a hydrogel, wherein the sweat permeation layer is in contact with the plurality of electrodes and configured to transfer the sweat containing the analyte through the sweat permeation layer to reach the plurality of electrodes for detection and/or energy harvesting.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
78.
SELF-POWERED TRIBOELECTRIC MXENE-BASED 3D-PRINTED WEARABLE PHYSIOLOGICAL BIOSIGNAL SENSING SYSTEM FOR ON-DEMAND, WIRELESS, AND REAL-TIME HEALTH MONITORING
A self-powered system for continuous real-time physiological signal monitoring. The system may comprise a charging component configured to generate power from movement of the user, and one or more pressure sensors applied to a user, operatively coupled to the charging component, configured to measure one or more physiological signals of the user and output one or more capacitance values. The charging component may be further configured to power the one or more pressure sensors, and the one or more pressure sensors may comprise MXene. The charging component may comprise an MXene-based triboelectric nanogenerator.
Disclosed herein are methods and compositions for the identification of viability enhancing cell features and substrate features as they relate to post-cryopreservation survival of substrate seeded cells. Embodiments of the present invention further involve identification of cell features to manufacture a supernatant that is useful for cell culturing and treatment of various diseases.
Methods for generating patterned nanoparticle assemblies in thin films of supramolecular nanocomposites are provided that allow control over microdomain morphology, periodicity, and orientation by tuning the assembly kinetics and pathways of the system. Directed self-assembly (DSA) of block copolymers (BCPs) with nanoparticles formed on lithographically-patterned templates produce patterned supramolecular nanocomposite films and patterns of nanoparticles. DSA may be used to guide the formation of concentric rings with radii spanning approximately 150 nm to 1150 nm and ring widths spanning about 30 nm to 60 nm, for example. When plasmonic nanoparticles are used, ring nanodevice arrays can be fabricated in one step, and the completed devices produce high-quality orbital angular momentum (OAM).
G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfaces; Materials therefor, e.g. comprising photoresists; Apparatus specially adapted therefor
B29C 33/38 - SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING - Details thereof or accessories therefor characterised by the material or the manufacturing process
B29C 71/00 - After-treatment of articles without altering their shape; Apparatus therefor
B29C 33/42 - SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING - Details thereof or accessories therefor characterised by the shape of the moulding surface, e.g. ribs or grooves
B29C 39/00 - Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressure; Apparatus therefor
B29C 39/02 - Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressure; Apparatus therefor for making articles of definite length, i.e. discrete articles
B29D 11/00 - Producing optical elements, e.g. lenses or prisms
81.
Novel CYP3A4-Specific Inhibitors and Methods of Using Same
The present invention provides novel compounds and compositions thereof inhibiting cytochrome P450 3A4 (CYP3A4). The present invention further provides a novel method of inhibiting CYP3A4 in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention. In one embodiment, the subject is further administered at least one additional therapeutic agent.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Board of Supervisors of Louisiana State University and Agricultural and Mechanical College (USA)
The Regents of the University of California (USA)
Inventor
Rider, Paul Jay Fannin
Hai, Rong
Kousoulas, Konstantin
Abstract
In Provided are embodiments of a recombinant nucleic acid comprising a nucleotide sequence encoding a live-attenuated kin chimeric Herpes Simplex Vims Type-1 (HSV-1) VC2 virus and a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter, wherein the heterologous polypeptide can replace the glycoprotein C (gC) openreading frame (ORF) in VC2, and wherein the nucleotide sequence encoding the heterologous polypeptide can encode the influenza virus hemagglutinin A or a fragment thereof. The constructs may be incorporated in a vaccine effective in generating antibodies against influenza hemagglutinin.
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
83.
METHODS OF DEPOSITING ALUMINUM NITRIDE TEMPLATING LAYERS USING THERMAL PULSED CHEMICAL VAPOR DEPOSITION FOR THE ENHANCEMENT OF ALUMINUM NITRIDE THICK FILMS AND RELATED FILMS
This invention allows for the deposition of aluminum nitride buffer layers and templating films that greatly enhance the quality of additional aluminum nitride deposited by alternate deposit ion techniques and reduce the overall thickness of needed buffer layers. Furthermore, these films can be deposited at substrate temperatures of 400° C. and 580° C. which is considerably lower than other techniques, such as molecular beam epitaxy (MBE) and metal organic chemical vapor deposition (MOCVD).
C23C 28/04 - Coating for obtaining at least two superposed coatings either by methods not provided for in a single one of main groups , or by combinations of methods provided for in subclasses and only coatings of inorganic non-metallic material
84.
CHEMICAL RECYLING OF PLASTICS USING IONIC LIQUIDS OR DEEP EUTECTIC SOLVENTS
National Technology and Engineering Solutions of Sandia, LLC (USA)
Inventor
Dou, Chang
Choudhary, Hemant
Sun, Ning
Simmons, Blake A.
Abstract
A method for depolymerizing a mixture of plastics is described. The method comprises (a) providing a composition comprising two of more plastics, (b) introducing a solvent comprising an ionic liquid (IL) or deep eutectic solvents (DES) and optionally water to the composition to form a solvent-plastic composition, such as an aqueous solvent-plastic composition, and (c) incubating the solvent-plastic composition for a period of time to produce a depolymerized composition such that at least portions of the two of more plastics are depolymerized into monomers. The produced monomers can be used as a carbon source for microbes to produce bioproducts.
C08J 11/28 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic compounds containing nitrogen, sulfur or phosphorus
C08J 11/16 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with inorganic material
The present disclosure presents sealant compositions which can be used in the treatment of an ocular surface injury and methods of treating an ocular surface injury in a subject in need thereof. The sealant compositions can include methacrylated hyaluronic acid (MeHA); GelMA; optionally, poly(ethylene glycol) diacrylate (PEGDA); and a visible light-activated photoinitiator. The methods include applying a sealant composition to an applicator; placing the applicator containing the sealant composition onto a surface of the eye of a subject, wherein the surface of the eye has or is suspected of having the ocular surface injury; and photo-crosslinking the sealant composition by exposing the applicator and the sealant composition to a visible light, for example, a visible light having a wavelength of about 400 nanometers (nm) to 800 nm.
The disclosed embodiments provide a system that performs molecular assembly. During operation, the system delivers one or more droplets of a fluid onto a surface using a nanofluidic delivery probe and an associated high-precision positioning device, wherein the solution comprises a solvent and one or more solute molecules, and wherein delivery of the droplets onto the surface facilitates evaporation-driven assembly of one or more structures on the surface. Moreover, while delivering a droplet onto the surface, the system controls a size of the droplet and a shape of the droplet during evaporation to produce a variety of shapes in resulting structures.
B29C 64/112 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using individual droplets, e.g. from jetting heads
B82B 3/00 - Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
B33Y 30/00 - ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING - Details thereof or accessories therefor
B33Y 50/02 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
B33Y 70/00 - Materials specially adapted for additive manufacturing
The present disclosure generally provides methods of implanting an implantable device in contact with a brain of a subject. Also provided are kits and systems for the implantation of one or more implantable devices.
Modulation, preferably inhibition, of neurosignaling of a cardiac-related sympathetic nerve in the extracardiac intrathoracic neural circuit is effective in stabilizing cardiac electrical and/or mechanical function, thereby providing ways of treating or preventing cardiac dysfunction such as arrhythmias.
The present disclosure relates to compounds that are capable of upregulating sAPPα and/or stabilizing reticulon-3. The disclosure further relates to methods of treating neurodegenerative diseases and disorders (e.g., Alzheimer's disease).
C07C 237/20 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
90.
Method for Rapid and Large-Scale Generation of Droplets and Droplet Libraries
Provided is a method of generating droplets that includes aspirating a first liquid into a tube, positioning the tube over a receiving liquid, and ejecting the first liquid to generate a plurality of droplets that contact the receiving liquid and remain discrete even after contacting the receiving liquid. Whereas many other droplet generators require complex microfluidics, the present methods allow generation of droplets without the need for microfluidics. The methods can be performed with existing commercially available macro-fluidic liquid handling devices. The methods can be used for digital PCR, digital MDA, enzyme screening, single cell analysis, and other applications involving droplets.
A low power-consumption iontronic pressure sensor is disclosed that is based on OECT where an ionic hydrogel is used as solid gating medium for pressure sensing transistor elements formed thereon. The pressure sensor includes a substrate containing one or more pressure sensing transistor elements with each transistor element including a source electrode, a drain electrode, and a channel formed from a material comprising an electrically conducting polymer. A microstructured solid gel electrolyte having a plurality of microstructures formed thereon serves as the gating medium and is disposed atop the channel. A gate electrode is disposed on the microstructured solid gel electrolyte. The resultant iontronic pressure sensor may be operated at voltages less than 1 V, with a power-consumption between ˜101-103 μW, while maintaining a tunable sensitivity between 1˜10 kPa−1.
The Trustees of the University of Pennsylvania (USA)
The Regents of the University of California (USA)
Inventor
Jariwala, Deep
Lynch, Jason
Kumar, Pawan
Barrera, Francisco
Davoyan, Artur
Abstract
Two-dimensional (2D) crystals have renewed opportunities in artificial lattice design and assembly without the constraints of epitaxy. However, the lack of thickness control in exfoliated van der Waals (vdW) layers prevents realization of repeat units with high fidelity. Uniform, wafer-scale samples permits engineering of both electronic and optical dispersions in stacks of disparate 2D layers with multiple repeating units. Systems, methods, and devices present optical dispersion engineering in a superlattice structure including alternating layers of 2D excitonic chalcogenides and dielectric insulators. Examples demonstrate >90% narrowband absorption in <4 nm active layer excitonic absorber medium at room temperature, concurrently with enhanced photoluminescence in cm2 samples. These superlattices show evidence of strong light-matter coupling and exciton-polariton formation with geometry-tunable coupling constants. The results demonstrate proof of concept structures with engineered optical properties and pave the way for a broad class of scalable, designer optical metamaterials from atomically-thin layers.
H01L 31/0352 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by their semiconductor bodies characterised by their shape or by the shapes, relative sizes or disposition of the semiconductor regions
H01L 31/076 - Multiple junction or tandem solar cells
H01L 31/032 - Inorganic materials including, apart from doping materials or other impurities, only compounds not provided for in groups
G02F 1/017 - Structures with periodic or quasi periodic potential variation, e.g. superlattices, quantum wells
G02F 1/015 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour based on semiconductor elements with at least one potential jump barrier, e.g. PN, PIN junction
93.
ATLAS-BASED CHARACTERIZATION OF PATENT-SPECIFIC CARDIAC ELECTROMECHANICAL ACTIVATION MAPS
A method may include generating, based on a plurality of electrophysiology simulations such as electrical and/or electromechanical activation maps, one or more atlases including an activation time (AT) atlas and a vectorcardiogram (VCG) atlas. The atlases may be generated by applying a dimensionality reduction technique to include one or more modes of variation present in the electrophysiology simulations. The atlases may be applied to match a clinical vectorcardiogram of a patient to a simulated vectorcardiogram associated with an activation map included in the electrophysiology simulations. At least one of a diagnosis or treatment for the patient may be determined based on the activation map. Related systems and computer program products are also provided.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
94.
Combination Therapeutics Comprising Nrf2 Agonists and Antivirals for Treating Viral Infections
Disclosed herein are compositions, kits, and methods employing combinations of (a) one or more Nrf2 agonists; and (b) one or more 3CLpro inhibitors, one or more protease inhibitors, and/or one or more N4-hydroxycytidine nucleoside to treat, inhibit, and/or reduce infections and symptoms caused by infection by a virus such as viruses belonging to the Coronaviridae family (e.g., coronaviruses), Orthomyxoviridae family, the Picornaviridae family, and the Pneumoviridae family of viruses.
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A method for determining a Lower Grade Glioma (LGG) subtype for a subject. A device for determining an LGG subtype in a subject. A system using machine learning for determining a Lower Grade Glioma (LGG) subtype in a subject.
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
96.
BIOMARKERS FOR CONFORMATION OF RIDING TRAITS IN HORSES
The invention relates to a method for determining, in a sample comprising nucleic acid molecules obtained from the horse, presence or absence of at least one biomarker useful in predicting conformation of back and croup and/or gait quality and/or gait type trot or pace of the horse. The at least one biomarker is located in a region of from nucleotide position 44,000,000 to nucleotide position 47,000,000 on Equus caballus chromosome 22 (ECA22).
The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 405/10 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 491/056 - Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
98.
USE OF SYNTHETIC COPOLYPEPTIDE HYDROGELS AS DERMAL FILLERS
Provided herein are synthetic copolypeptide hydrogel compositions for use as dermal fillers, and methods of treating dermatological conditions using the same.
The invention provides cells that have an increased Signal Regulatory Protein Alpha (SIRPαα) engagement function (SIRPα engager cells) that resist innate immunity when transplanted into a subject when compared to a parental cell having an unmodified SIRPα engagement function. The SIRPα engager cells lack an intact CD47 cytoplasmic signalling function. In some embodiments, the SIRPα engager cells are hypoimmune cells. In other embodiments, the SIRPα engager cells are differentiated somatic cells. In other embodiments, the SIRPα engager cells are hypoimmune pluripotent (HIP) cells. In further embodiments, the HIP cells are blood type O (HIPO), Rhesus factor (Rh)negative (HIP−) or both type O and Rh− (HIPO−). In other embodiments, the SIRPα engager cells have been derived or differentiated from HIP, HIP−, or HIPO− cells. In other embodiments, the SIRPα engager cells comprise an antibody Fc receptor to protect against antibody dependent cellular cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC). In other embodiments, the SIRPα engager cells evade ADCC or CDC via elevated cell surface CD16, CD32, or CD64 expression.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The Board of Regents of the University of Oklahoma (USA)
Inventor
Lanier, Lewis L.
Hildebrand, William H.
Abstract
The present invention provides vaccine compositions for preventing and/or treating cytomegalovirus (CMV) infection and methods of making and using the same.